Patents by Inventor Minyi Zhou

Minyi Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interferon alpha mutant and its polyethylene glycol derivative
    Patent number: 8901277
    Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: December 2, 2014
    Assignees: Beijing Tri-Prime Genetic Engineering Co., Ltd, Beijing Bio-Tech Development Co., Ltd.
    Inventors: Jinyi Liu, Xiaoxia Niu, Minyi Zhou, Yi Yang, Jianbo Sun, Yongqing Cheng
  • INTERFERON ALPHA MUTANT AND ITS POLYETHYLENE GLYCOL DERIVATIVE
    Publication number: 20130287733
    Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
    Type: Application
    Filed: March 27, 2012
    Publication date: October 31, 2013
    Applicants: BEIJING BIO-TECH DEVELOPMENT CO., LTD., BEIJING TRI-PRIME GENETIC ENGINEERING CO., LTD.
    Inventors: Jinyi LIU, Xiaoxia NIU, Minyi ZHOU, Yi YANG, Jianbo SUN, Yongqing CHENG
  • Interferon alpha mutant and its polyethylene glycol derivative
    Patent number: 8168751
    Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: May 1, 2012
    Assignees: Beijing Tri-Prime Genetic Engineering Co., Ltd., Beijing Bio-Tech Development Co., Ltd.
    Inventors: Jinyi Liu, Xiaoxia Niu, Minyi Zhou, Yi Yang, Jianbo Sun, Yongqing Cheng
  • INTERFERON ALPHA MUTANT AND ITS POLYETHYLENE GLYCOL DERIVATIVE
    Publication number: 20100074866
    Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
    Type: Application
    Filed: December 21, 2007
    Publication date: March 25, 2010
    Applicants: BEIJING TRI-PRIME GENETIC ENGINEERING CO., LTD., BEIJING BIO-TECH DEVELOPMENT CO., LTD.
    Inventors: Jinyi Liu, Xiaoxia Niu, Minyi Zhou, Yi Yang, Jianbo Sun, Yongqing Cheng